Pricing Log in Create free account
Saturday 17 October 2026 Export ABBV’s income statement to Excel — free account

AbbVie Inc.

ABBV Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

285.42 2.02 +0.71%
Market cap
$500.8B
P/E
80.6×
Fwd P/E
27.8×
Dividend yield
2.42%
F-score
8/9
Altman Z
2.31
Beneish M
−2.86
Dividend safety
44/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

AbbVie Inc. (ABBV) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, AbbVie Inc. (ABBV) trades at a EV/EBITDA of 22.2×. Over the past ten years it has ranged from 8.2× (March 2020) to 28.7× (July 2015); the current reading is higher than 94% of that period. That is above the Drug Manufacturers General industry median of 13.8× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 19.4× 13.45%
FY2024 17.1× 33.36%
FY2023 12.8× (0.28%)
FY2022 12.9× 10.87%
FY2021 11.6× (19.32%)
FY2020 14.4× 36.44%
FY2019 10.5× (50.78%)
FY2018 21.4× 27.98%
FY2017 16.7× 33.69%
FY2016 12.5× (12.41%)

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 19.9× 7.51%
Mar 2026 18.5× (4.48%)
Dec 2025 19.4× (7.23%)
Sep 2025 20.9× 26.36%
42 more quarters

Against its own ten years

Low 8.2× High 28.7×
Ten-year median 14.2×
Current reading's percentile 94

EV/EBITDA against peers

Company EV/EBITDA
PFE Pfizer Inc. compare 10.8×
AZN AstraZeneca PLC compare 13.8×
NVS Novartis AG compare 14.5×
AMGN Amgen Inc. compare 16.8×
JNJ Johnson & Johnson compare 18.1×
ABBV AbbVie Inc. 22.2×
MRK Merck & Co., Inc. compare 29.5×
LLY Eli Lilly and Company compare 32.7×
GILD Gilead Sciences, Inc. compare 829×
Drug Manufacturers General industry median 13.8×
Healthcare sector median 9.2×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on ABBV